This benefit was also evident in a trial comparing pembrolizumab to chemotherapy in patients diagnosed with aNSCLC and PD-L1 expression above 1%, although the gain was mainly driven by tumours with high PD-L1 levels [3]. The gene discussed is CD274; the disease is neoplasm.